U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

9 articles about U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

• 

  U.S. Intelligence Report on COVID-19 Origins Expected Today

  8/24/2021

  President Biden is expected to be briefed on the lab leak theory conducted over the last 90 days. Very few expect solid results, although this might provide direction for more lines of inquiry.

• Sarepta Therapeutics Announces Research Agreement with U.S. Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as Treatments for COVID-19

  4/28/2020

  Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Company and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), the Department of Defense’s lead laboratory for medical biological defense research, have entered into a Cooperative Research and Development Agreement (CRADA). The purpose of the CRADA is to jointly identify antisense ol

• TFF Pharmaceuticals Announces Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for use of its Thin Film Freezing Technology Platform

  4/15/2020

  USAMRIID to study use of TFF technology to formulate dry powder neutralizing antibodies and vaccines against national priority biodefense threats for pulmonary delivery AUSTIN, Texas--( BUSINESS WIRE )-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, has entered into a Cooperativ

• BioDiem Ltd. Extends Co-Operative Agreement With USAMRIID

  2/14/2013

• ZyGEM Corporation and USAMRIID Sign Crada for Development of Simplified Sample Processing Solutions for Biothreat Agents

  1/5/2012

• Biomatrica and USAMRIID Sign a CRADA for the Development of New Technologies Applicable for Ambient Stabilization of Clinical and Biological Samples

  7/28/2011

• Antidote To Lethal Germ 'Closer', Brookhaven National Laboratory and USAMRIID Study

  5/13/2008

• CytoGenix, Inc. and USAMRIID to Collaborate in Developing Biodefense synDNA(TM) Vaccines

  3/27/2007

• AVI BioPharma And USAMRIID Announce NEUGENE Antisense Drug Demonstrates Efficacy Against Ebola Virus

  11/1/2004